Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11849090 | 0.91 | CYP3A4 (0.46) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL1493105 | 0.83 | TDP1 (0.44) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL9629412 | 0.83 | TDP1 (0.44) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL9742778 | 0.81 | MAPK1 (0.39) | TDP1MAPK1CYP3A4AHR | |
| SCHEMBL4881789 | 0.81 | CYP3A4 (0.50) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL28559413 | 0.81 | TDP1 (0.42) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL11475560 | 0.81 | CYP3A4 (0.55) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL29862583 | 0.80 | CYP3A4 (0.54) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| SCHEMBL93182 | 0.80 | CYP3A4 (0.54) | TDP1MAPK1CYP3A4ALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL28180433 | 0.78 | CYP3A4 (0.52) | TDP1MAPK1CYP3A4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115386245-A | Preparation method and application of lipophilic carbon nitride nanosheet | 浙江理工大学 | 2022-11-25 | — | — | CN | claimed |
| JP-8291153-A | — | — | None | — | — | JP | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2026799-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | Galapagos SAS (FR) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137874-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2007-12-06 | — | — | WO | disclosed |
| JP-H08291153-A | PRODUCTION OF 1-(2-CHLOROPHENYL)5-(4H)-TETRAZOLINONE | NIPPON BAYERAGROCHEM KK | 1996-11-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | TDP1 2743/4885MAPK1 2962/4885CYP3A4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.